EDGAR Filing Documents for 0001193125-24-138893

Form 8-K - Current report:

SEC Accession No. 0001193125-24-138893

Filing Date

2024-05-15

Accepted

2024-05-15 07:40:54

Documents

Period of Report

2024-05-13

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	d839821d8k.htm iXBRL	8-K	66489
2	EX-3.1	d839821dex31.htm	EX-3.1	6039
3	EX-3.2	d839821dex32.htm	EX-3.2	30111
4	EX-99.1	d839821dex991.htm	EX-99.1	10939
8	GRAPHIC	g839821dsp17.jpg	GRAPHIC	4973
	Complete submission text file	0001193125-24-138893.txt		273146

Data Files

Seq	Description	Document	Type	Size
5	XBRL TAXONOMY EXTENSION SCHEMA	syre-20240513.xsd	EX-101.SCH	2832
6	XBRL TAXONOMY EXTENSION LABEL LINKBASE	syre-20240513_lab.xml	EX-101.LAB	19502
7	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	syre-20240513_pre.xml	EX-101.PRE	12144
20	EXTRACTED XBRL INSTANCE DOCUMENT	d839821d8k_htm.xml	XML	3973

Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453

Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940

Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)